![]() |
市场调查报告书
商品编码
1829246
2025年POC Hba1C检测全球市场报告Poc Hba1C Testing Global Market Report 2025 |
近年来,POC Hba1C 检测市场规模快速扩张,从 2024 年的 9.2 亿美元成长至 2025 年的 10.2 亿美元,复合年增长率达 10.6%。这段时期的成长可归因于新兴市场的强劲经济成长、糖尿病盛行率的上升、新冠疫情病例的增加以及可支配收入的增加。
预计未来几年,POC Hba1C 检测市场规模将快速成长,到 2029 年将达到 15.9 亿美元,复合年增长率为 11.7%。预测期内的成长归因于政府支持力度的加大、糖尿病(2 型糖尿病)盛行率的上升、POC 检测的便捷性以及与传统实验室检测相比,POC 检测结果出炉速度更快。预测期间的主要趋势包括:Hba1C微流体萤光检测的关注度、家用 Hba1C检测套组的使用率不断提高、使用毛细管电泳技术进行 Hba1C 检测的关注度以及检测技术的进步。
Poc Hba1C 检测设备旨在诊断和管理患者的 1 型和 2 型糖尿病。糖尿病是一种慢性疾病,当胰臟无法产生足够的胰岛素或无法有效利用其产生的胰岛素时就会发生。 Poc Hba1C 检测可评估患者两到三个月内的平均血糖值。
POC Hba1C 检测产品主要包括仪器和耗材。仪器是用于测定分析物现值的测量设备。 POC Hba1C 检测技术包括离子交换高效液相层析法 (HPLC)、酵素检测法、亲和结合层析法和免疫比浊抑制免疫检测。这些检测设备被各种终端使用者使用,包括医院、医生诊所、门诊中心和居家照护机构。
2025年春季美国关税的突然上调及其引发的贸易摩擦对医疗设备行业产生了重大影响,尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制涨价,製造商面临利润压力。监管挑战使情况更加复杂,因为由于关税而更换供应商通常需要医疗设备重新认证,导致市场进入延迟。为此,企业正在透过双重采购关键零件、增加标准化产品的国内生产以及加快寻找更具成本效益的材料来降低风险。
本研究报告是商业研究公司 (The Business Research Company) 新报告系列的一部分,该系列提供 Poc Hba1C 检测市场统计数据,例如全球市场规模、区域份额、Poc Hba1C 检测市场份额的竞争对手、详细的 Poc Hba1C 检测细分市场、市场趋势和商机,以及您在 Poc Hba1C 检测行业取得成功所需的数据。本 Poc Hba1C 检测市场研究报告对该行业的现状和未来趋势进行了详细分析,为您提供所需的一切观点。
我们预测未来五年该市场将成长11.7%,较我们先前对该市场的预测略有下降0.3%。这一下降主要源自于美国与其他国家之间关税的影响。这种影响可能会直接影响美国,导致主要从德国和日本进口的血红蛋白结合试剂和微流体晶片成本上升,导致糖尿病照护现场监测设备价格上涨。由于互惠关税以及日益加剧的贸易紧张局势和限制对全球经济和贸易的负面影响,这种影响也将更加广泛。
糖尿病盛行率的上升预计将推动照护现场(POC) HbA1c 检测市场的成长。长时间工作、体力活动减少和不健康饮食等因素导致糖尿病发生率上升。 POC HbA1c 检测可以在社区环境或医疗机构中进行糖尿病诊断和监测,而无需实验室。例如,2024 年 6 月,英国国家医疗服务体系 (NHS) 报告称,40 岁以下确诊患有糖尿病的患者人数从 2022 年的 173,166 人增加到 2023 年的 216,440 人。这一显着增长表明这个年龄组出现了令人不安的趋势,反映了年轻人中糖尿病患病率的快速上升。因此,糖尿病盛行率的上升正在刺激 POC HbA1c 检测市场的扩张。
预计政府支持将在预测期内显着促进即时糖化血红蛋白(POC Hba1C)检测市场的扩张。政府不断加大力度,提高民众对现有医疗保健解决方案的认识,正在推动整体市场的成长。 2022年8月,肯亚政府与丹麦製药公司诺和诺德签署了一份谅解备忘录,将为儿童第1型糖尿病的治疗和自我护理提供医疗用品。合作内容包括:糖尿病诊所基础建设、医疗设备和检测设备供应、医疗保健专业人员培训,以及向儿童和青少年免费提供胰岛素和血糖监测用品。政府的持续支持预计将推动即时糖化血红蛋白(POC Hba1C)检测市场的发展。
技术进步是推动即时糖化血红蛋白 (POC) 检测市场发展的显着趋势。主要市场参与者正在投资开发能够提供快速且准确结果的先进技术,帮助实验室应对日益增长的检测需求。美国知名医疗设备和医疗保健公司雅培 (Abbott) 推出了 Afinion HbA1c Dx 检测试剂盒。此体外诊断试剂盒专为 Afinion 2 分析仪和 Afinion AS100 分析仪设计,已获得美国FDA 批准,是唯一一款可协助医疗保健专业人员诊断糖尿病和评估患者风险的快速即时糖化血红蛋白检测试剂盒。 Afinion HbA1c Dx检测法盒仅需三分钟即可提供可靠的糖化血红蛋白检测结果,方便用户在一次就诊中快速评估并制定个人化治疗计划。
家用糖化血红蛋白 (HbA1c)检测套组的兴起已成为即时糖化血红蛋白 (POC) 检测领域的一个发展趋势,为患者提供了在家中采集血液样本的便利性。这些套件允许使用者将样本送至实验室进行分析,为糖尿病患者监测血糖控制提供了一种方便的选择。为因应 COVID-19 疫情,美国医疗保健公司 Labcorp 推出了糖尿病风险 (HbA1c) 家用采集检测产品,使糖尿病患者能够在家中管理病情,同时最大限度地减少接触病毒的机会。这种向家用检测的转变表明,POC Hba1C 检测能够适应不断变化的医疗保健需求。
2022 年 8 月,美国生物技术研究公司 Precision Diabetes, Inc. 与韩国诊断产品製造商 DxGen Corp. 在美国达成独家伙伴关係关係。此次合作将专注于 Epithod AutoDx 的销售,这是一款自动化即时诊断 (POC) 分析仪,可分析全面的糖尿病测试概况。该系统设计用于小型实验室、门诊和医院,可即时提供可操作的测试结果。 Precision Diabetes 利用先进的糖尿病生物标记和演算法实现精准糖尿病医疗,而 DxGen 是全球即时诊断 (POC) 製造商。此次伙伴关係凸显了双方在推动 POC Hba1C 检测创新方面的全球合作。
Poc Hba1C 检测市场的主要企业包括 F.Hoffmann-La Roche Ltd、Siemens Healthineers AG、Bio-Rad Laboratories Inc、Menarini Group、Danaher Corporation、Tosoh Bioscience Inc、ARKRAY Inc、i-SENS, Inc、Abbott Laboratories、Trinity Biotech plc、Aina Bloodtech Monteching System、Altech, Montech Monx, Montechkx Inc、bioMerieux、EKF Diagnostics、HemoCue、PTS Diagnostics、Diazyme Laboratories、Osang Healthcare、Ortho Clinical Diagnostics、Ascensia、Platinum Equity (LifeScan)、Becton Dickinson and Company、Medtronic PLC、Kainico Ltd. Brasun Technologies、Bainico Ltd. Bainama。
2024年,北美是POC Hba1C检测市场最大的地区。预计非洲将成为预测期内成长最快的地区。 POC Hba1C检测市场报告涵盖以下地区:亚太地区、西欧、中欧和东欧、北美、南美以及中东和非洲。
Poc Hba1C 检测市场报告涵盖的国家有澳洲、巴西、中国、法国、德国、印度、印尼、日本、俄罗斯、韩国、英国、美国、义大利、西班牙和加拿大。
POC Hba1C 检测市场涵盖小型、可携式和 HbA1C 检测设备的销售。该市场的价值为“出厂价”,即商品製造商或生产商向其他营业单位(包括下游製造商、批发商、经销商和零售商)或直接向最终客户销售的商品价值。该市场中的商品价值还包括商品製造商销售的任何相关服务。
POC HbA1C testing devices are designed for diagnosing average levels of glucose in patients' blood and managing both type I and type II diabetes mellitus. Diabetes is a chronic disease that occurs when either an inadequate amount of insulin is produced by the pancreas or when the body cannot use the insulin it produces effectively. POC HbA1C testing assesses the average level of blood sugar over 2 to 3 months in an individual.
The main products of POC HbA1C testing include instruments and consumables. Instruments refer to measuring devices for determining the present value of a quantity under observation. The technologies involved in POC HbA1C testing include ion-exchange HPLC, enzymatic assay, affinity binding chromatography, turbidimetric inhibition immunoassay, and others. Various end-users utilize these testing devices, including hospitals, physician offices or outpatient centers, home care providers, and other end-users.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The Poc Hba1C testing market research report is one of a series of new reports from The Business Research Company that provides Poc Hba1C testing market statistics, including Poc Hba1C testing industry global market size, regional shares, competitors with a Poc Hba1C testing market share, detailed Poc Hba1C testing market segments, market trends and opportunities, and any further data you may need to thrive in the Poc Hba1C testing industry. This Poc Hba1C testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The poc hba1c testing market size has grown rapidly in recent years. It will grow from $0.92 billion in 2024 to $1.02 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to strong economic growth in emerging markets, an increase in diabetes prevalence, a rise in COVID-19 cases, and an increase in disposable income.
The poc hba1c testing market size is expected to see rapid growth in the next few years. It will grow to $1.59 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to rising government support, increasing prevalence of diabetes- type ii diabetes, easy accessibility of POC tests, and faster availability of results in POC testing than conventional laboratory testing procedures. Major trends in the forecast period include a focus on hba1c microfluidic immunofluorescence test, increasing use of home collection hba1c testing kits, focus on the hba1c test using capillary electrophoresis technology, and advances in testing technologies.
The forecast of 11.7% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through increased costs for hemoglobin-binding reagents and microfluidic cassettes, primarily imported from Germany and Japan, leading to higher prices for diabetes monitoring at point-of-care.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising prevalence of diabetes is expected to drive the growth of the point-of-care (POC) HbA1c testing market. Factors such as long working hours, reduced physical activity, and unhealthy dietary habits are contributing to the increasing rates of diabetes. POC HbA1c assays allow for the diagnosis and monitoring of diabetes in community settings and healthcare facilities without the need for laboratories. For instance, in June 2024, the National Health Service (NHS), a UK-based government department, reported that the number of individuals under 40 diagnosed with diabetes rose from 173,166 in 2022 to 216,440 in 2023. This significant increase indicates a troubling trend in this age group and reflects a rapid rise in diabetes prevalence among younger populations. Consequently, the growing prevalence of diabetes is fueling the expansion of the POC HbA1c testing market.
Government support is poised to be a significant contributor to the expansion of the POC HbA1c testing market in the forecast period. Increased government initiatives to enhance public awareness about available healthcare solutions are bolstering overall market growth. In August 2022, the government of Kenya entered a memorandum of understanding with Novo Nordisk, a Denmark-based pharmaceutical company, aiming to supply medical commodities for the treatment and self-care of type 1 diabetes in children. The collaboration involves improving diabetes clinics' infrastructure, supplying medical and laboratory equipment, training healthcare professionals, and providing free insulin and blood glucose monitoring supplies to children and teenagers. This growing government support is expected to be a driving factor for the POC HbA1c testing market.
Technological advancements represent a notable trend gaining traction in the POC HbA1C testing market. Major market players are channeling investments into developing advanced technologies to provide rapid and accurate results, helping laboratories manage the increasing demand for testing. Abbott, a prominent U.S.-based medical devices and healthcare company, introduced the Afinion HbA1c Dx assay. This in vitro diagnostic test, designed for the Afinion 2 Analyzer and Afinion AS100 Analyzer, is the only rapid POC test cleared by the U.S. FDA to aid healthcare professionals in diagnosing diabetes and assessing the patient's risk. Delivering reliable results of glycated hemoglobin in just three minutes, the Afinion HbA1c Dx assay facilitates quick evaluation and individualized care planning during a single doctor's visit.
The rise of home collection HbA1c testing kits has emerged as a growing trend in POC HbA1c testing, offering patients the convenience of collecting blood samples at home. These kits allow users to send their samples to a laboratory for analysis, providing a accessible option for monitoring blood glucose control in diabetes patients. Labcorp, an American healthcare company, introduced the Diabetes Risk (HbA1c) at-home collection test in response to the COVID-19 pandemic, allowing diabetic patients to manage their condition at home while minimizing exposure to the virus. This shift towards home testing demonstrates the adaptability of POC HbA1c testing to changing healthcare needs.
In August 2022, Precision Diabetes, Inc., a U.S.-based biotechnology research company, and DxGen Corp., a South Korea-based diagnostic manufacturing company, formed an exclusive partnership in the United States. The collaboration aims to market Epithod AutoDx, an automated POC analyzer that analyzes a comprehensive profile of diabetes tests. The system is designed for use in smaller laboratories, outpatient clinics, and hospitals, providing real-time actionable test findings for practitioners. Precision Diabetes, Inc. utilizes advanced diabetic biomarkers and algorithms for precision medicine in diabetes, while DxGen Corp. is a global manufacturer of Point-Of-Care (POC) diagnostics. This partnership underscores the global collaboration driving innovation in POC HbA1c testing.
Major companies operating in the Poc Hba1C testing market include F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Bio-Rad Laboratories Inc, Menarini Group, Danaher Corporation, Tosoh Bioscience Inc, ARKRAY Inc, i-SENS, Inc, Abbott Laboratories, Trinity Biotech plc, Aina Blood Monitoring System, Getein Biotech Inc, Sugentech, Inc, Alere Inc, bioMerieux, EKF Diagnostics, HemoCue, PTS Diagnostics, Diazyme Laboratories, Osang Healthcare, Ortho Clinical Diagnostics, Ascensia, Platinum Equity (LifeScan), Becton Dickinson and Company, Medtronic PLC, Kainico Ltd, Evia Medical Technologies, Agamatrix Inc, Bionime Corporation, B Braun Melsungen AG.
North America was the largest region in the POC HbA1C testing market in 2024. Africa is expected to be the fastest-growing region in the forecast- period. The regions covered in the POC hba1c testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the POC hba1c testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The POC HbA1C testing market consists of sales of small instruments, portable instruments, and HbA1C testing devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Poc Hba1C Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on poc hba1c testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for poc hba1c testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The poc hba1c testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.